, protecting downstream chromatography columns from fouling. Capture Step: Protein A Chromatography
Today, we are diving into a hypothetical but realistic case study of a monoclonal antibody targeting a specific inflammatory marker. We will explore the critical decision points that process engineers face when scaling a biologic from the bench to the bioreactor.
The relentless push for more efficient bioprocessing is driven by economics, and the integration of continuous manufacturing is a game-changer. Continuous biopharmaceutical manufacturing is expected to grow by as much as between now and 2033 due to its ability to improve efficiency and reduce costs compared to batch processing.
Butyl Sepharose – used only if aggregates > 1.5% after CEX. A Mab A Case Study In Bioprocess Development
50 kg → $3M direct manufacturing cost.
The final stage is implementing a to ensure the process remains within the design space. This combines traditional testing with modern approaches like Process Analytical Technology (PAT) for real-time monitoring.
From the QTPP, engineers identify —the chemical, physical, or biological properties that must remain within strict limits to ensure patient safety and efficacy. For mAb A, the CQAs include: , protecting downstream chromatography columns from fouling
) rather than just cell density. Key findings included the influence of specific amino acids on reducing acidic species, a common post-translational modification that can affect mAb efficacy. 2.3. Bioreactor Scale-Up and Control Strategy
The A-Mab case study set the stage for subsequent industry collaborations, such as the project, which continues to refine these tools for the next generation of bioprocess community. It remains essential reading for CMC (Chemistry, Manufacturing, and Controls) professionals and regulatory scientists. If you'd like to dive deeper, let me know if you want:
The development team shifts from a traditional batch process to a fed-batch process with a chemically defined, animal-component-free medium. Using Design of Experiments (DoE), they optimize the feed strategy: The relentless push for more efficient bioprocessing is
The purified Mab-X is now in a low-pH, high-salt buffer unsuitable for injection. The case study addresses two final challenges:
No bioprocess case study is complete without analytics. The Mab-X team implements a real-time process analytical technology (PAT) framework: